



NeuroVista Named One of Washington's 100 Best Companies to Work For by *Seattle Business* Magazine

Seattle, WA—June 18, 2009—NeuroVista Corporation, a medical device company pioneering new technologies for the management and treatment of epilepsy, today announced it has been named one of Washington's 100 Best Companies to Work For by *Seattle Business* magazine. This is the second year that the company has made the list, placing 16th in the Small Company category and 30th place overall.

“We are honored once again to receive this important recognition,” said John F. Harris, President and Chief Executive Officer of NeuroVista. “NeuroVista takes a great deal of pride not only in our mission of developing innovative technologies to improve the lives of people living with epilepsy, but also in our company culture which is based on core values emphasizing respect, teamwork and open communication. We believe that developing a great place to work is fundamental not only in recruiting and retaining the best talent in the region, but also in creating world-class products.”

“The companies in our top 100 Best Companies to Work For list are companies that have built healthy workplace cultures,” said Leslie D. Helm, Editor of *Seattle Business*. “These companies let employees know what is expected of them, evaluate them fairly, and allow them to live a well-balanced life.”

Seattle Business is Washington's leading business monthly magazine, covering business, industry and public policy issues that impact the state's economy. It provides content in print and online at www.seattlebusinessmag.com.

About NeuroVista

NeuroVista is an early-stage medical device company pioneering new technologies for the management and treatment of epilepsy, a condition that affects nearly three million people in the United States. NeuroVista is engaged in developing innovative advisory technologies to help mitigate the uncertainty of when epileptic seizures strike, which may significantly impact the quality of life of people living with epilepsy and dramatically shift the treatment paradigm.

NeuroVista is emerging as a leading innovator in the rapidly growing field of implantable neurotechnology with a large portfolio of issued patents and pending patent applications. The company is funded by a top-tier group of venture investors including Advanced Technology Ventures, Delphi Ventures, Foundation Medical Partners, Sprout Group, and Three Arch Partners. NeuroVista is headquartered in downtown Seattle, Washington. For more information visit www.neurovista.com.